Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)
Completed
Braintree Laboratories
Phase 3
2006-08-01
The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid
Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in
infants age 30 days up to 1 year.
Weight Gain Management in Patients With Schizophrenia
Completed
Eli Lilly and Company
Phase 4
2003-02-01
Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with
schizophrenia who have been under treatment with olanzapine for at least two months and
evaluate the treatment effects on the Eating Inventory, BPRS, number of treatment, emergent
adverse events, changes in vital signs, laboratory results and extrapyramidal effects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
